BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 1627417)

  • 1. Systemic therapy in node-negative patients: updated findings from NSABP clinical trials. National Surgical Adjuvant Breast and Bowel Project.
    Fisher B; Redmond C
    J Natl Cancer Inst Monogr; 1992; (11):105-16. PubMed ID: 1627417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials.
    Fisher B; Jeong JH; Anderson S; Wolmark N
    J Natl Cancer Inst; 2004 Dec; 96(24):1823-31. PubMed ID: 15601638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18.
    Fisher ER; Wang J; Bryant J; Fisher B; Mamounas E; Wolmark N
    Cancer; 2002 Aug; 95(4):681-95. PubMed ID: 12209710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors.
    Fisher B; Redmond C; Dimitrov NV; Bowman D; Legault-Poisson S; Wickerham DL; Wolmark N; Fisher ER; Margolese R; Sutherland C
    N Engl J Med; 1989 Feb; 320(8):473-8. PubMed ID: 2644531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indications for breast-preserving surgery and adjuvant therapy in early breast cancer.
    Posner MC; Wolmark N
    Int Surg; 1994; 79(1):43-7. PubMed ID: 8063554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials.
    Taghian A; Jeong JH; Mamounas E; Anderson S; Bryant J; Deutsch M; Wolmark N
    J Clin Oncol; 2004 Nov; 22(21):4247-54. PubMed ID: 15452182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors.
    Fisher B; Costantino J; Redmond C; Poisson R; Bowman D; Couture J; Dimitrov NV; Wolmark N; Wickerham DL; Fisher ER
    N Engl J Med; 1989 Feb; 320(8):479-84. PubMed ID: 2644532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized clinical trials.
    Taghian AG; Jeong JH; Mamounas EP; Parda DS; Deutsch M; Costantino JP; Wolmark N
    J Clin Oncol; 2006 Aug; 24(24):3927-32. PubMed ID: 16921044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant treatment for early breast cancer: the Ludwig breast cancer studies.
    Goldhirsch A; Gelber R
    NCI Monogr; 1986; (1):55-70. PubMed ID: 3774016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved survival for women with stage I breast cancer in south-east Sweden: a comparison between two time periods before and after increased use of adjuvant systemic therapy.
    Johansson P; Fohlin H; Arnesson LG; Dufmats M; Nordenskjöld K; Nordenskjöld B; Stål O;
    Acta Oncol; 2009; 48(4):504-13. PubMed ID: 19235568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
    Hillner BE
    Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil.
    Fisher B; Dignam J; Mamounas EP; Costantino JP; Wickerham DL; Redmond C; Wolmark N; Dimitrov NV; Bowman DM; Glass AG; Atkins JN; Abramson N; Sutherland CM; Aron BS; Margolese RG
    J Clin Oncol; 1996 Jul; 14(7):1982-92. PubMed ID: 8683228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma: final analysis with 10-year follow-up.
    Assikis V; Buzdar A; Yang Y; Smith T; Theriault R; Booser D; Valero V; Walters R; Singletary E; Ames F; Hortobagyi G
    Cancer; 2003 Jun; 97(11):2716-23. PubMed ID: 12767083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute toxicity during adjuvant chemotherapy for breast cancer: the National Surgical Adjuvant Breast and Bowel Project (NSABP) experience from 1717 patients receiving single and multiple agents.
    Glass A; Wieand HS; Fisher B; Redmond C; Lerner H; Wolter J; Shibata H; Plotkin D; Foster R; Margolese R; Wolmark N
    Cancer Treat Rep; 1981; 65(5-6):363-76. PubMed ID: 7016322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis.
    Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
    Cancer; 2006 Jun; 106(12):2576-82. PubMed ID: 16703595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.
    Mamounas EP; Bryant J; Lembersky B; Fehrenbacher L; Sedlacek SM; Fisher B; Wickerham DL; Yothers G; Soran A; Wolmark N
    J Clin Oncol; 2005 Jun; 23(16):3686-96. PubMed ID: 15897552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant CMF for node-negative and estrogen receptor-negative breast cancer patients.
    Zambetti M; Bonadonna G; Valagussa P; Daidone MG; Coradini D; Bignami P; Contesso G; Silvestrini R
    J Natl Cancer Inst Monogr; 1992; (11):77-83. PubMed ID: 1627434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-year results of International Breast Cancer Study Group Trial IV.
    Crivellari D; Price K; Gelber RD; Castiglione-Gertsch M; Rudenstam CM; Lindtner J; Fey MF; Senn HJ; Coates AS; Collins J; Goldhirsch A;
    J Clin Oncol; 2003 Dec; 21(24):4517-23. PubMed ID: 14673038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.